The treatment of HIV has evolved over the last 40 years to a point where the life expectancies of people with HIV rival those without the disease. Typically, people older than 50 years of age are considered “older adults” or “aging” in the HIV literature. In this new reality, the focus is not only on HIV treatment but the comprehensive management of all comorbid conditions. Major comorbidities in this population include cardiovascular disease, hypertension, diabetes mellitus, and malignancy. HIV medications must now be selected to maximize the quality of all disease treatments, especially considering the effect that chronic inflammation, immune activation, and immunosenescence associated with HIV can have on comorbidities. Aging also may be accompanied by physiologic changes that can affect drug exposure or response. Age-related changes in pharmacokinetics and pharmaco-dynamics must be considered. Providers must go “beyond undetectable” when considering the management of HIV in this population.
Read the full review at Infectious Disease Special Edition.
Source : Infectious Disease Special Edition
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.